|
Age (year), mean (SD)
|
76 (5)
|
78 (5)**
|
76 (5)
|
76 (5)
|
78 (5)**
|
76 (5)
|
|
Female, n (%)
|
268 (59%)
|
23 (50%)
|
245 (60%)
|
224 (55%)
|
19 (49%)
|
224 (60%)
|
|
Participants with plasma biomarkers measured in the first year, n (%)
|
420 (93%)
|
44 (96%)
|
376 (93%)
|
382 (93%)
|
37 (95%)
|
345 (93%)
|
|
Initial body mass index, mean (SD)
|
26.4 (4.0)
|
25.9 (3.8)
|
26.5 (3.9)
|
26.4 (3.8)
|
25.6 (3.1)
|
26.5 (3.9)
|
|
Initial CCS, mean (SD)
|
0.07 (0.79)
|
− 0.25 (0.70)**
|
0.10 (0.79)
|
0.10 (0.77)
|
− 0.20 (0.71)*
|
0.14 (0.78)
|
|
Initial MMSE, mean (SD)
|
27.8 (1.9)
|
27.5 (1.7)
|
27.9 (1.9)
|
27.9 (1.8)
|
27.7 (1.6)
|
27.9 (1.8)
|
|
Initial gait speed (m/s), mean (SD)
|
1.0 (0.2)
|
1.0 (0.3)
|
1.0 (0.2)
|
1.0 (0.2)
|
1.0 (0.3)
|
1.0 (0.2)
|
|
Initial chair-stand time (s), mean (SD)
|
12.1 (4.3)
|
12.9 (4.0)
|
12.0 (4.4)
|
12.0 (4.3)
|
12.9 (4.2)
|
11.9 (4.3)
|
|
Aβ42/Aβ40 ratio, mean (SD)
|
0.114 (0.018)
|
0.097 (0.010)**
|
0.116 (0.018)
|
0.113 (0.018)
|
0.096 (0.010)**
|
0.115 (0.018)
|
|
NfL (pg/ml), mean (SD)
|
86.65 (74.09)
|
160.35 (137.01)**
|
78.30 (57.79)
|
85.70 (75.50)
|
162.55 (143.15)**
|
77.62 (59.23)
|
